(Q35041013)

6 August 2017

title

Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials (English)

1 reference

6 August 2017

1 reference

2

Roy S Herbst

1 reference

6 August 2017

Donald A Berry

1

1 reference

6 August 2017

Eric H Rubin

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2012

1 reference

6 August 2017

published in

Clinical Cancer Research

1 reference

6 August 2017

volume

18

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

638-644

1 reference

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314693

The BATTLE trial: personalizing therapy for lung cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314693

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314693

Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314693

Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314693

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314693

8 July 2018

Bayesian clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314693

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314693

Gene expression profiling predicts clinical outcome of breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314693

The cross-validated adaptive signature design

8 July 2018

1 reference

12 December 2020

Adaptive clinical trials: the promise and the caution

1 reference

12 December 2020

Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group

1 reference

12 December 2020

Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients

1 reference

12 December 2020

10.1158/1078-0432.CCR-11-2018

Identifiers

DOI

1 reference

6 August 2017

1 reference

6 August 2017

1 reference